MEDIFAST INC (MED) Medifast, Inc., through its various divisions, develops and provides a range of consumable health and nutritional items tailored for weight loss, weight management, and general wellness. These products are distributed across the United States and the Asia-Pacific region. Their extensive portfolio encompasses snack bars, savory bites, cereals, drinks, substantial meal choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, baked goods, and soups. These offerings are marketed under proprietary brands like OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home. The company facilitates sales primarily through direct e-commerce transactions. Established in 1980, Medifast, Inc. maintains its corporate headquarters in Baltimore, Maryland.
Sector: Miscellaneous Food Preparations & Kindred Products
Industry: Personal Products & Services
Medifast, Inc. NYSE:MED Consumer Cyclical · Personal Products & Services
AH Close $12.09 vs close AH Close $12.09 -0.17% vs close
All Press Release SEC Filings News
Press Release ● Major ⚠ 5
Medifast Announces Third Quarter 2026 Financial Results
Medifast reported Q3 2026 revenue of $72.0 million, down 19.4% year-over-year, with a GAAP net loss of $17.5 million ($1.57 per share) versus a $2.3 million loss a year ago.
Active earning coaches fell 47.7% to 10,200 on continued client-acquisition pressure from GLP-1 medication adoption, though revenue per coach rose 54.1% to $7,064 and non-GAAP adjusted loss narrowed to $2.1 million ($0.19 per share).
The Catalyst Restructuring drove $15.4 million of charges, inflating GAAP losses while adjusted SG&A fell 16.0%; the balance sheet holds $172.5 million in cash and investments with no debt.
Management guided Q4 revenue of $55-75 million with income per share of $0.00-$0.25 and said it is on track to deliver profitability in the fourth quarter.
• 16h ago AI analysis › Press Release
Why Is Weight Loss Different During Menopause? Common Myths Debunked
globenewswire.com • 11d ago Press Release
Medifast to Announce Financial Results for the Third Quarter Ended September 30, 2026
Medifast (NYSE: MED) will announce financial results for the quarter ended September 30, 2026 on Monday, October 26, 2026, before market open.
A conference call hosted by CEO Nick Johnson and CFO Jim Maloney is scheduled for 8:30 a.m. ET the same day, with a live webcast on the company's investor relations site and a telephonic replay available through November 2, 2026.
The release contains no financial results; it is a routine earnings-date scheduling notice.
• 12d ago AI analysis › Press Release
5 Questions People Ask When Every Weight Loss Approach Has Failed
globenewswire.com • 13d ago Press Release
What Actually Keeps Weight Off After a Weight Loss Program
globenewswire.com • 18d ago News
Can Medifast's Better Client Retention Support Revenue Stabilization?
zacks.com • 20d ago Press Release
Why Do You Keep Gaining Weight Back After Losing It
globenewswire.com • 20d ago Press Release
What Are the 5 Signs of Poor Metabolic Health Adults May Overlook?
globenewswire.com • 25d ago Press Release
Why Weight Loss Plateaus Happen: 5 Metabolic Causes
globenewswire.com • 27d ago News
Medifast's 3.0 Strategy Takes Shape: Can It Restore Profitable Growth?
zacks.com • 1mo ago News
Why Is Medifast (MED) Down 7.6% Since Last Earnings Report?
zacks.com • 1mo ago Press Release ⚠ 2
Ocius Technology to Add Sonar Systems to Bluebottle Fleet: NYSE Content Update
The New York Stock Exchange, a subsidiary of FILER Intercontinental Exchange (NYSE: ICE), issued its routine pre-market floor advisory for September 2, 2026 — a TV programming note rather than a company disclosure.
The featured segment is Ocius Technology integrating sonar systems supplied by ThayerMayhan and Thales Australia into its Bluebottle fleet, with Ocius CEO Robert Dane slated to appear on NYSE Live.
Medifast (NYSE: MED) is also featured, launching the Medifast Metabolic Health Institute as it repositions beyond weight loss, and ringing the closing bell to mark its 20th listing anniversary; Hornbeck Offshore rings the opening bell.
Market color only: the 10-year Treasury yield hit its highest level since 2023 and ICE Brent Crude traded near $94 a barrel — nothing in the release affects Intercontinental Exchange fundamentals.
• 1mo ago AI analysis › Press Release
Medifast® Announces the Launch of the Medifast Metabolic Health Institute™
Medifast launched the Medifast Metabolic Health Institute to advance metabolic health through rigorous research and education, leveraging 45 years of clinical history.
The institute consolidates the company's expertise, including 40 peer-reviewed scientific journal publications and 18 randomized controlled trials, to substantiate its Metabolic Synchronization science.
This initiative follows the July rebrand to Trilivy and aims to set scientific standards for coach certification, reinforcing Medifast's authority in the metabolic health space.
• 1mo ago AI analysis › News
Can Medifast Capitalize on Rising GLP-1 Use With Metabolic Health?
zacks.com • 2mo ago News
All You Need to Know About Medifast (MED) Rating Upgrade to Buy
zacks.com • 2mo ago SEC Filing ⚠ 2
MED: SCHEDULE 13D/A · ownership disclosure
Steamboat Capital Partners, LLC and its managing member Parsa Kiai filed Amendment No. 1 to their Schedule 13D on Medifast Inc, reporting beneficial ownership of 790,693 shares, a 7.1% stake, with sole voting and dispositive power over the entire position.
The amendment discloses continued open-market accumulation: 33,994 shares bought on August 19, 2026 at a weighted average of about $11.66, and 50,000 shares on August 20, 2026 at about $11.60, bringing the aggregate cost of the reported position to approximately $8,360,835.
The 7.1% percentage is based on 11,180,703 shares outstanding as of July 27, 2026, per Medifast's 10-Q filed August 3, 2026. A Schedule 13D rather than a 13G signals potential active intent, though this amendment contains no stated demands or plans.
An activist holding more than 7% of a small-cap weight-loss company trading near $11.60 sets up a potential catalyst — watch for a follow-up 13D/A or proxy filing that adds Item 4 purpose-of-transaction language or board demands.
SEC SCHEDULE 13D/A • 2mo ago AI analysis › News
Can Medifast's New Compensation Plan Accelerate Coach Growth?
zacks.com • 2mo ago News
Can Medifast's Coach Productivity Gains Help Revive Revenue Growth?
zacks.com • 2mo ago News
Is MED Worth Buying as Low Valuation Meets a High-Risk Turnaround?
zacks.com • 2mo ago News
MED Rallies 13.6% in the Past Month: Can the Momentum Keep Building?
zacks.com • 2mo ago News
Can MED's Trilivy Launch and Cost Cuts Drive a Q4 Profit Turnaround?
zacks.com • 2mo ago News
Medifast: Worth A Speculative Entry As Sales Stabilize (Rating Upgrade)
seekingalpha.com • 2mo ago News
Medifast Q2 Loss Narrower Than Expected, Coach Productivity Improves
zacks.com • 2mo ago News
Medifast, Inc. (MED) Q2 2026 Earnings Call Transcript
seekingalpha.com • 2mo ago News
Medifast Q2 Earnings Call Highlights
marketbeat.com • 2mo ago News
Medifast (MED) Reports Q2 Loss, Beats Revenue Estimates
zacks.com • 2mo ago Press Release ● Major ⚠ 4
Medifast Announces Second Quarter 2026 Financial Results
Medifast reported Q2 revenue of $76.4 million, down 27.6% year-over-year, with a net loss of $3.1 million or $0.28 per share.
The decline was driven by a 48.7% drop in active earning coaches to 11,700, attributed to GLP-1 medication adoption, though revenue per coach improved 41% to $6,529.
The balance sheet remains solid with $169.8 million in cash and no debt, while management guided for a return to profitability in Q4.
• 2mo ago AI analysis › News
Medifast Stock to Post Q2 Earnings: What Investors Should Know
zacks.com • 2mo ago News
Medifast (MED) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
zacks.com • 2mo ago Press Release
Medifast to Announce Financial Results for the Second Quarter Ended June 30, 2026
Medifast will announce its financial results for the second quarter ended June 30, 2026, on August 3, 2026, after the market closes.
The company will host a conference call at 4:30 p.m. ET on the same day, featuring CEO Nick Johnson and CFO Jim Maloney.
The call will be webcast on the Medifast investor relations website and archived online through November 3, 2026.
• 3mo ago AI analysis › News
Will Medifast's Trilivy Launch Unlock a New Growth Chapter?
zacks.com • 3mo ago Press Release ⚠ 2
Medifast® Enters a New Era: Introducing Trilivy™, a Science-Backed Metabolic Health System
Medifast announced the launch of Trilivy, a comprehensive metabolic health system marking a major corporate transition from its legacy OPTAVIA brand.
The new system features MetaVantage Technology and claims a 14% reduction in visceral fat and 98% retention of lean mass over 16 weeks in clinical studies.
Newly formulated meal replacements called Fuelings are planned to debut in August as the company shifts its focus from weight loss to broader metabolic health.
• 3mo ago AI analysis › News
Medifast (MED) Loses 18.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
zacks.com • 4mo ago Press Release
Metabolic Health After 40: What Perimenopause and Menopause Mean for Weight Management
globenewswire.com • 4mo ago Press Release
What Science-Backed Subscription Health Programs Measure Differently
globenewswire.com • 4mo ago News
Medifast (MED) Down 5.1% Since Last Earnings Report: Can It Rebound?
zacks.com • 4mo ago News
Is MEDIFAST (MED) Stock Outpacing Its Consumer Staples Peers This Year?
zacks.com • 4mo ago SEC Filing
MED: 8-K · leadership change
Medifast, Inc. announced the resignation of Jason L. Groves as Chief Legal Officer and Corporate Secretary, effective May 29, 2026. The company stated that his departure was not the result of any disagreement with the company regarding operations, policies, or practices.
Groves entered into a separation agreement on May 31, 2026, entitling him to a one-time lump sum severance payment of $35,648.42, which equals one month of his annual base salary. Medifast has commenced a search for a permanent replacement for the Chief Legal Officer role.
SEC 8-K • 4mo ago AI analysis › Press Release
Medifast Confirms Appointment of Nicholas Johnson as Chief Executive Officer
Medifast has formally appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026.
Johnson succeeds Dan Chard, who will step down as CEO but remain as Chairman of the Board to provide strategic oversight.
The transition follows a plan disclosed in January, with Johnson having served as President since early 2026 to ensure continuity.
• 5mo ago AI analysis › Press Release
Weight Loss Coaching vs. App-Only Programs: What Published Research Shows About Long-Term Outcomes
globenewswire.com • 5mo ago Press Release
Peer-Reviewed Research Is Redefining Weight Loss Program Standards
globenewswire.com • 5mo ago Press Release
Peer-Reviewed Research Shows Structured Meal Replacement Programs Support Visceral Fat Reduction and Lean Mass Preservation
globenewswire.com • 5mo ago News
Why Medifast's $15 Cash Per Share Makes It A Strong Buy
seekingalpha.com • 5mo ago News
Medifast: Worth Putting On A Watchlist
seekingalpha.com • 5mo ago News
Medifast Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
zacks.com • 5mo ago News
Medifast, Inc. (MED) Q1 2026 Earnings Call Transcript
seekingalpha.com • 5mo ago News
Medifast (MED) Reports Q1 Loss, Tops Revenue Estimates
zacks.com • 5mo ago Press Release ⚠ 4
Medifast Announces First Quarter 2026 Financial Results
Medifast reported Q1 2026 revenue of $76.0 million, down 34.3% year-over-year, with a net loss of $0.19 per share compared to a $0.07 loss in the prior year.
The decline was driven by a 44.9% drop in active earning coaches to 14,000, attributed to client acquisition challenges and competition from GLP-1 weight-loss medications.
The company issued weak guidance for FY 2026, projecting revenue of $270 million to $300 million and a net loss per share of $1.55 to $2.75.
• 5mo ago AI analysis › News
Medifast's Q1 Earnings on The Horizon: Key Insights for Investors
zacks.com • 5mo ago Recent SEC filings with analysis 
